Toshihiko Imamura
Kyoto Prefectural University of Medicine
Internal medicinePathologyOncologyPediatricsHematologyImmunologyChemotherapyPrednisoloneHematopoietic stem cell transplantationLangerhans cell histiocytosisB cellLeukemiaChildhood leukemiaAcute lymphocytic leukemiaRegimenTransplantationCancer researchMedicineBiologyGastroenterology
Publications 203
#1Judith M. BoerH-Index: 28
#2Maria Grazia Valsecchi (University of Milan)H-Index: 75
Last. Andishe Attarbaschi (Medical University of Vienna)H-Index: 35
view all 0 authors...
#1Yunchao Chang (St. Jude Children's Research Hospital)H-Index: 4
#2Jaeki Min (St. Jude Children's Research Hospital)H-Index: 16
Last. Kathryn G. Roberts (St. Jude Children's Research Hospital)H-Index: 33
view all 0 authors...
ABSTRACT null null CRLF2-rearranged (CRLF2r) acute lymphoblastic leukemia (ALL) comprises over half of Philadelphia chromosome-like (Ph-like) ALL, is associated with poor outcome in children and adults. Overexpression of CRLF2 results in activation of JAK-STAT and parallel signaling pathways in experimental models, but existing small molecule inhibitors of Janus kinases show variable and limited efficacy. Here we evaluated the efficacy of proteolysis-targeting chimeras (PROTACs) directed against...
#1Hiroaki Kondo (Kyoto Prefectural University of Medicine)
#2Takuyo KanayamaH-Index: 2
Last. Hajime Hosoi (Kyoto Prefectural University of Medicine)H-Index: 33
view all 8 authors...
#1Shinsuke Hirabayashi (Hokkaido University)H-Index: 9
#2Ellie Butler (Newcastle University)H-Index: 3
Last. Atsushi Manabe (Hokkaido University)H-Index: 20
view all 24 authors...
1 CitationsSource
#1Shunsuke Nakagawa (Kadai: Kagoshima University)H-Index: 4
#2Motohiro KatoH-Index: 34
Last. Yasuhiro OkamotoH-Index: 1
view all 14 authors...
Induction deaths (ID) remain a critical issue in the treatment of pediatric patients with acute lymphoblastic leukemia (ALL). The reported rate of ID in this population is 1% or higher. We speculate that this proportion might be lower in Japan because of mandatory hospitalization during induction therapy to manage complications. We retrospectively analyzed the incidence of ID among children with ALL enrolled in 4 Japanese study groups between 1994 and 2013. Among 5620 children, 41 (0.73%) cases ...
#1Hisashi Ishida (Okayama University)H-Index: 7
#2Mio YanoH-Index: 8
Last. Toshihiko Imamura (Kyoto Prefectural University of Medicine)H-Index: 22
view all 12 authors...
Approximately 90% of pediatric acute lymphoblastic leukemia (ALL) cases are curable with intensified chemotherapy, but very high-risk patients may require hematopoietic stem cell transplantation (HSCT). A suitable indication for HSCT in the first complete remission (CR1) should be defined to protect patients from long-term complications. We report the outcomes of HSCT in CR1 from the Japan Association of Childhood Leukemia Study (JACLS) ALL-02 study and reassess indications for HSCT. Of 1114 pat...
#1Kenichi SakamotoH-Index: 7
#2Akira Morimoto (Jichi Medical University)H-Index: 41
Last. Shinsaku ImashukuH-Index: 61
view all 5 authors...
Langerhans cell histiocytosis (LCH) is a rare inflammatory myeloid neoplasia derived from immature myeloid dendritic cells with the mitogen-activated protein kinase (MAPK) pathway gene mutation. LCH is rarely fatal, but patients develop various permanent consequences (PCs). We report the frequencies of LCH-related PCs in paediatric patients (n = 317) treated by the JLSG-96/02 AraC-containing regimens. One-third of LCH patients had at least one PC at a median follow-up of 12 years. Central nervou...
#1Yaqi Zhao (St. Jude Children's Research Hospital)H-Index: 4
#2Ibrahim Aldoss (City of Hope National Medical Center)H-Index: 21
Last. Kathryn G. Roberts (St. Jude Children's Research Hospital)H-Index: 33
view all 19 authors...
Blinatumomab, a bispecific antibody that directs CD3+ T cells to CD19+ tumor cells shows variable efficacy in B-progenitor acute lymphoblastic leukemia (B-ALL). To determine tumor-intrinsic and extrinsic determinants of response, we studied 44 adults with relapsed or refractory B-ALL (including two MRD positive) treated with blinatumomab using bulk tumor and single-cell sequencing. The overall response rate in patients with hematological disease was 55%, with a high response rate CRLF2-rearrange...
8 CitationsSource
#1Yukari Sakurai (Asahikawa Medical University)H-Index: 1
#2Takeo Sarashina (Asahikawa Medical University)H-Index: 5
Last. Hiroshi Azuma (Asahikawa Medical University)H-Index: 24
view all 10 authors...
A 9-year-old girl was diagnosed with B-cell precursor-acute lymphoblastic leukemia (BCP-ALL). Although she entered remission after induction therapy, she relapsed 15 months after maintenance therapy cessation. Since further investigation revealed EBF1-PDGFRB fusion, her condition was treated as BCR-ABL1-like acute lymphoblastic leukemia. She was started on a tyrosine kinase inhibitor, imatinib, and chemotherapy and underwent umbilical cord blood transplantation following reduced intensity condit...
#1Monique L. Den BoerH-Index: 41
#2Gunnar CarioH-Index: 34
Last. Rob PietersH-Index: 106
view all 24 authors...
Summary Background ABL-class fusion genes other than BCR–ABL1 have been identified in approximately 3% of children with newly diagnosed acute lymphocytic leukaemia, and studies suggest that leukaemic cells carrying ABL-class fusions can be targeted successfully by tyrosine-kinase inhibitors. We aimed to establish the baseline characteristics and outcomes of paediatric patients with ABL-class fusion B-cell acute lymphocytic leukaemia in the pre-tyrosine-kinase inhibitor era. Methods This multicen...
3 CitationsSource